Triple

T22796999
Position Surface form Disambiguated ID Type / Status
Subject AveXis E564274 entity
Predicate usesVector P37227 FINISHED
Object AAV9 NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: AAV9 | Statement: [AveXis, usesVector, AAV9]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: AAV9
Context triple: [AveXis, usesVector, AAV9]
  • A. AveXis
    AveXis is a biotechnology company best known for developing the gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy.
  • B. human adenovirus serotype 26 (Ad26)
    Human adenovirus serotype 26 (Ad26) is a non-replicating viral vector commonly used in vaccine development to deliver genetic material encoding target antigens and stimulate an immune response.
  • C. E*Vax
    E*Vax is the stage name of Evan Mast, an American electronic musician and producer best known as one half of the duo Ratatat.
  • D. HCV NS5A protein
    HCV NS5A protein is a multifunctional nonstructural hepatitis C virus protein essential for viral RNA replication and assembly, and a key target of several direct-acting antiviral drugs.
  • E. CAAV
    CAAV is the national regulatory body responsible for overseeing and managing civil aviation activities in Vietnam.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: AAV9
Target entity description: AAV9 is a serotype of adeno-associated virus widely used as a gene therapy vector, particularly valued for its ability to efficiently deliver genetic material to cells in the central nervous system and other tissues.
  • A. AveXis
    AveXis is a biotechnology company best known for developing the gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy.
  • B. human adenovirus serotype 26 (Ad26)
    Human adenovirus serotype 26 (Ad26) is a non-replicating viral vector commonly used in vaccine development to deliver genetic material encoding target antigens and stimulate an immune response.
  • C. E*Vax
    E*Vax is the stage name of Evan Mast, an American electronic musician and producer best known as one half of the duo Ratatat.
  • D. HCV NS5A protein
    HCV NS5A protein is a multifunctional nonstructural hepatitis C virus protein essential for viral RNA replication and assembly, and a key target of several direct-acting antiviral drugs.
  • E. CAAV
    CAAV is the national regulatory body responsible for overseeing and managing civil aviation activities in Vietnam.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2458185f88190b0045227ee420411 completed April 17, 2026, 2:36 p.m.
NER Named-entity recognition batch_69f17cd9b3c0819096050f43a829ec0d completed April 29, 2026, 3:36 a.m.
Created at: April 17, 2026, 3:30 p.m.